Cyclenium Pharma
Cyclenium Pharma is the Canadian Subsidiary of SpiroChem AG.
It is deploying its proprietary next generation CMRT™ small-molecule macrocycle technology for drug discovery against difficult disease targets. As a Contract Research Organization, Cyclenium is offering solutions to innovative pharmaceutical and biotechnology companies worldwide who want to explore macrocycles as new modalities.
About Cyclenium
Cyclenium was founded by management and research staff from Tranzyme Pharma, one of the pioneers in the generation and use of small molecule macrocycles for drug discovery. Tranzyme was the first company to prepare and use large screening libraries (50,000+) of synthetic macrocyclic compounds to identify and optimize multiple lead candidates that progressed to late stage clinical trials (Phase 2b, Phase 3). Subsequent to Tranzyme’s merger with Ocera Therapeutics (now part of Mallinckrodt Plc (NYSE: MNK)) and closure of its Canadian R & D site, the founders created, based on their vast experience, profound knowledge base in macrocyclic chemistry, and exceptional track record of successful lead and clinical candidate generation, a proprietary next generation technology that addresses the deficiencies of earlier efforts in this rapidly growing field. Since May 2023 and the acquisition by SpiroChem AG, Cyclenium is providing access to its proprietary platform to customers.
Company Milestones
- May 2023: Acquisition of Cyclenium Pharma by SpiroChemAG
- January 2022: Drug discovery collaboration with Vuja De Sciences (U.S.) for targeting of metastatic cancer recurrence.
- May 2020: Awarding of a major grant from the U.S. Department of Defense to support late stage discovery research on the company’s pan-flaviviral inhibitors
- October 2018: Discovery collaboration with AiCuris (Germany) for anti-infective pharmaceuticals
- September 2018: Funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) received for joint anti-viral program with Haplogen
- September 2018: Collaborative project with Haplogen Biosciences on pan-flaviviral therapeutics recognized with EUREKA label
- December 2017: Drug discovery collaboration agreement established with Ono Pharmaceutical (Japan)
- March 2017: Research agreement on multiple targets formed with the Hospital for Sick Children (Toronto)
- July 2016: Beyond Europe grant received from the Austrian Research Promotion Agency (FFG) for joint project with Haplogen GmbH
